PharmaFocus: Biomarkers in Alzheimer's Disease

1
PharmaFocus Biomarkers in Alzheimer's Disease
One-Stop Shop for Business Information
2
Summary
Alzheimers disease (AD) is a progressive
neurodegenerative disease that is characterized
by memory loss, cognitive impairment, and
functional decline. The disease has emerged as a
major global health priority especially because
of its rapidly accelerating prevalence worldwide.
In order to tackle the AD scourge , there is an
urgent need for tools that will allow for the
early and accurate diagnosis of AD, as well as
the identification of populations at risk. A
biomarker is an indicator of biological processes
that can be objectively measured and evaluated,
and well-validated biomarkers are required to
satisfy these needs in AD.The search for
biomarkers that are reflective of the disease
process in AD has been and continues to be an
active area of research, but has been hampered by
a lack of clear understanding of the pathological
mechanisms that underlie the disease.
3

• Nonetheless, several biomarkers have been
  developed to date that indicate the presence of
  AD pathology and AD-associated neuronal injury in
  vivo. Such biomarkers have the potential for
  clinical use in etiological determination,
  predictive prognosis, monitoring disease
  progression, and in clinical trials of potential
  disease-modifying therapies for AD.
• Scope
• Overview of Alzheimer's disease, including
  disease etiology and pathophysiology and how
  these inform biomarker targets. - Overview of AD
  biomarkers, the major classes of biomarkers an
  the different potential roles of biomarkers in
  clinical use and drug development.
• - Key topics covered include amyloid biomarkers,
  tau biomarkers, and other molecular biomarkers
  for AD in development with product profiles for
  marketed as well as promising pipeline assays.

4

• Also discussed are functional and structural
  imaging biomarkers for AD.
• Analysis of the unmet needs, and opportunities
  within the AD biomarker arena, as well as drivers
  and barriers impacting the AD biomarker market.-
  Insightful review of the regulatory
  considerations impacting biomarker development,
  market access and use in clinical drug
  development
• Key Benefits
• Develop and design your in-licensing and
  out-licensing strategies through a review of
  pipeline products and technologies, and by
  identifying the companies with the most robust
  pipeline.
• Develop business strategies by understanding the
  factors shaping and driving AD biomarker
  development and market adoption.

5
Table Of Content

1. Table of Contents
2. Introduction
3. Alzheimers Disease Overview
4. AD Biomarkers Overview
5. Unmet Needs Assessment
6. AD Biomarkers Market Drivers and Barriers
7. Amyloid Beta Biomarkers
8. Tau-Related Biomarkers
9. Beyond Amyloid and Tau Other Molecular AD
   Biomarkers in Development
10. Functional Brain Imaging Biomarkers
11. Structural Brain Imaging Biomarkers

6

• To know more
• PharmaFocus Biomarkers in Alzheimer's Disease

Contact Us-Call India 91-22-27810772/73 Call
USA/Canada (Toll Free) 1-866-279-8368 Email id
info_at_bharatbook.com